What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials

Creative Commons License

Ureyen S. B., Ivory C., KALYONCU U., Karsh J., Aydin S. Z.

RHEUMATOLOGY ADVANCES IN PRACTICE, vol.2, no.1, 2018 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 2 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1093/rap/rkx019
  • Journal Name: RHEUMATOLOGY ADVANCES IN PRACTICE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Keywords: psoriatic arthritis, randomized controlled trials, outcomes, axial disease, enthesitis, dactylitis, inclusion criteria, ORAL PHOSPHODIESTERASE-4 INHIBITOR, PATIENT-REPORTED OUTCOMES, QUALITY-OF-LIFE, PLACEBO-CONTROLLED TRIAL, ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY, TERM 52-WEEK IMPROVEMENTS, CURRENT SKIN INVOLVEMENT, DOUBLE-BLIND, PHASE-III, DISEASE-ACTIVITY
  • Hacettepe University Affiliated: Yes

Abstract

Objective. PsA is a heterogeneous disease with various subtypes of joint manifestations, which can affect the homogeneity of randomized controlled trials (RCTs). The aim of this systematic literature review was to evaluate the inclusion criteria, demographics and outcomes of RCTs to see whether the whole spectrum of PsA was represented.